ASHPOfficial

In this episode, a father-daughter duo shares their pharmacy journeys. Meagan, a clinical pharmacy specialist in pain and palliative care at Parkland Hospital in Dallas, reflects on preparing for pharmacy school and residency, while her father, Daniel, vice president of pharmacy at Mercy, discusses supporting students, connecting STEM interests to pharmacy careers, and understanding the many paths the profession can offer. ASHP is a proud HOSA partner, dedicated to empowering future health professionals through education, collaboration, and experiences, and inspiring students to explore pharmacy and the career opportunities within the field.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Part four of the Tools of the Trade series, this episode focuses on tools and tips for data visualization. The episode highlights common tools used in data visualization and discusses common concepts. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Efforts to deregulate certain prescription drugs outside the Food and Drug Administration’s (FDA) established review framework are gaining momentum in several states, raising concerns about patient safety and regulatory consistency. This episode explores ASHP’s new policy opposing such legislative actions and highlights the risks of bypassing evidence‑based FDA pathways for Rx‑to‑over-the-counter (OTC) switches. We’ll also examine past attempts to move medications, such as statins and other drug classes, to OTC status and why these proposals did not meet FDA standards.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast discusses the Centers for Medicare & Medicaid Services (CMS) Outpatient Prospective Payment System (OPPS) proposed rule, with a focus on its cuts to the 340B Drug Pricing Program. We discuss CMS’s proposed cuts to 340B reimbursement and proposed changes to recoupment of 340B overpayments from 2018 – 2022, as well as how these changes interact with other challenges to the 340B program.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast, hosted by the Pharmacy Administration and Leadership Residents’ Collaborative (PALRC) and the Section of Pharmacy Practice Leaders (SPPL) will inform listeners about developing the pipeline from residents, mid-level managers, and upper-level pharmacy executives for hospital and health system pharmacy leadership by engaging two established pharmacy executives and two pharmacy administration and leadership residents. Listeners will learn perspectives on the leadership pipeline for health system pharmacy, key drivers, and thoughts on leadership considerations for the continued advancement of health system pharmacy practice. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast centers on actionable steps residency program directors (RPDs) can take to prepare for audits with fewer surprises. It highlights concrete practices — like tightening documentation workflows, tracking how dollars move through the institution, and building audit-ready files — that may help programs stay compliant while running more smoothly. The episode is designed as a straightforward refresher for RPDs who may benefit from more clarity on regulatory expectations.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This session discusses the potential sites of action and benefits for GLP-1 agonists (GLP-1a) in the pathology of two neurodegenerative disorders, Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). This session will also review the published and pending clinical literature of FDA approved GLP-1a use in AD and PD.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast focuses on on strategies to use technology to increase access to pharmacy care. Strategies include optimizing use of the electronic medical record for patient communication, use of prescription pick up kiosks to facilitate prescription access, and use of telepharmacy and remote pharmacies to promote pharmacy access. The positive impact to patient care will be highlighted throughout. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast evaluates the roles of intravenously (IV) administered vancomycin and IV or orally (PO) administered linezolid for the empiric management of suspected or confirmed infections caused by methicillin-resistant Staphylococcus aureus (MRSA). We discuss and compare the positive and negative attributes of each drug and how those impact their places in the therapeutic management of MRSA infections. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode explores how pharmacy residency programs can remain agile in a rapidly evolving recruitment environment. Leaders from UNC Health discuss their experiences evaluating applicant interest, workforce priorities, program resources, and preceptor capacity to guide decisions around modifying, creating, consolidating, and general residency program agility and strategic workforce planning with postgraduate year 1 and 2 residency positions.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.